Tscan Therapeutics Inc (TCRX)

Currency in USD
1.73
-0.02(-1.14%)
Closed·
After Hours
1.65-0.08(-4.60%)
·
TCRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 6 days
TCRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.681.78
52 wk Range
1.026.38
Key Statistics
Prev. Close
1.75
Open
1.77
Day's Range
1.68-1.78
52 wk Range
1.02-6.38
Volume
93.5K
Average Volume (3m)
571.38K
1-Year Change
-72%
Book Value / Share
3.71
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TCRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.00
Upside
+420.23%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Tscan Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Tscan Therapeutics Inc Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Compare TCRX to Peers and Sector

Metrics to compare
TCRX
Peers
Sector
Relationship
P/E Ratio
−0.7x−2.4x−0.5x
PEG Ratio
0.05−0.080.00
Price/Book
0.5x1.2x2.6x
Price / LTM Sales
22.1x4.9x3.3x
Upside (Analyst Target)
-308.2%42.8%
Fair Value Upside
Unlock31.9%6.5%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.00
(+420.23% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
-0.60 / -0.28
Revenue / Forecast
2.17M / 1.20M
EPS Revisions
Last 90 days

TCRX Income Statement

People Also Watch

0.6608
GOVX
-9.39%
16.24
SRPT
-3.04%
1.880
CRBU
-7.84%
0.760
PSTV
+15.47%
0.365
VYNE
+1.36%

FAQ

What Stock Exchange Does Tscan Therapeutics Trade On?

Tscan Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Tscan Therapeutics?

The stock symbol for Tscan Therapeutics is "TCRX."

What Is the Tscan Therapeutics Market Cap?

As of today, Tscan Therapeutics market cap is 97.90M.

What Is Tscan Therapeutics's Earnings Per Share (TTM)?

The Tscan Therapeutics EPS (TTM) is -2.32.

When Is the Next Tscan Therapeutics Earnings Date?

Tscan Therapeutics will release its next earnings report on 12 Aug 2025.

From a Technical Analysis Perspective, Is TCRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Tscan Therapeutics Stock Split?

Tscan Therapeutics has split 0 times.

How Many Employees Does Tscan Therapeutics Have?

Tscan Therapeutics has 201 employees.

What is the current trading status of Tscan Therapeutics (TCRX)?

As of 06 Aug 2025, Tscan Therapeutics (TCRX) is trading at a price of 1.73, with a previous close of 1.75. The stock has fluctuated within a day range of 1.68 to 1.78, while its 52-week range spans from 1.02 to 6.38.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.